Giant Biogene Holding (2367) Stock Overview
An investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty and health products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
2367 Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Giant Biogene Holding Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$27.04 |
| 52 Week High | HK$65.70 |
| 52 Week Low | HK$26.02 |
| Beta | 0.71 |
| 1 Month Change | -8.96% |
| 3 Month Change | -9.20% |
| 1 Year Change | -54.52% |
| 3 Year Change | -26.72% |
| 5 Year Change | n/a |
| Change since IPO | 1.27% |
Recent News & Updates
Giant Biogene Holding's (HKG:2367) Sluggish Earnings Might Be Just The Beginning Of Its Problems
The subdued market reaction suggests that Giant Biogene Holding Co., Ltd.'s ( HKG:2367 ) recent earnings didn't contain...Time To Worry? Analysts Are Downgrading Their Giant Biogene Holding Co., Ltd. (HKG:2367) Outlook
The analysts covering Giant Biogene Holding Co., Ltd. ( HKG:2367 ) delivered a dose of negativity to shareholders...Recent updates
Shareholder Returns
| 2367 | HK Personal Products | HK Market | |
|---|---|---|---|
| 7D | -1.2% | -0.8% | 0.2% |
| 1Y | -54.5% | -39.1% | 5.5% |
Return vs Industry: 2367 underperformed the Hong Kong Personal Products industry which returned -39.1% over the past year.
Return vs Market: 2367 underperformed the Hong Kong Market which returned 5.5% over the past year.
Price Volatility
| 2367 volatility | |
|---|---|
| 2367 Average Weekly Movement | 6.5% |
| Personal Products Industry Average Movement | 7.6% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 16.0% |
| 10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 2367 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2367's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 2,201 | Jianya Yan | www.xajuzi.com |
Giant Biogene Holding Co., Ltd., an investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty and health products in the People’s Republic of China. It offers functional skincare products, medical dressings and devices, and functional food products under the KOMFYMED, Collgene, Ke Yu, SKIGIN, and other brands. The company also develops and manufactures rare ginsenosides technology-based functional food products.
Giant Biogene Holding Co., Ltd. Fundamentals Summary
| 2367 fundamental statistics | |
|---|---|
| Market cap | HK$28.71b |
| Earnings (TTM) | HK$2.22b |
| Revenue (TTM) | HK$6.39b |
Is 2367 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2367 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.52b |
| Cost of Revenue | CN¥1.09b |
| Gross Profit | CN¥4.43b |
| Other Expenses | CN¥2.52b |
| Earnings | CN¥1.91b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.80 |
| Gross Margin | 80.34% |
| Net Profit Margin | 34.70% |
| Debt/Equity Ratio | 0% |
How did 2367 perform over the long term?
See historical performance and comparisonDividends
Does 2367 pay a reliable dividends?
See 2367 dividend history and benchmarks| Giant Biogene Holding dividend dates | |
|---|---|
| Ex Dividend Date | Jun 01 2026 |
| Dividend Pay Date | Jun 25 2026 |
| Days until Ex dividend | 13 days |
| Days until Dividend pay date | 11 days |
Does 2367 pay a reliable dividends?
See 2367 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/13 19:41 |
| End of Day Share Price | 2026/06/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Giant Biogene Holding Co., Ltd. is covered by 21 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Melinda Hu | Bernstein |
| Ethan Cui | BofA Global Research |
| Zhuonan Xu | China International Capital Corporation Limited |